COVID-19 pandemic has dramatic impact on osteoporosis management, finds new global study

With FRAX fracture risk calculations down by 58% in April 2020 alone, it is estimated that within a 3-month period, more than 0.5 million patients have been excluded from risk assessment -- and many from necessary treatment for osteoporosis

Newswise — A new study published prior to World Osteoporosis Day finds that the COVID-19 pandemic, which has severely affected management of non-communicable diseases, is markedly impacting the management of osteoporosis as judged by access to online FRAX fracture risk assessments.1,2

Globally, usage of the Fracture Risk Assessment Tool (FRAX®) website was on average 58% lower in April than in February 2020.

FRAX is used to generate 10-year probabilities of fracture at the hip or major skeletal sites using clinical risk factors, with or without bone mineral density (BMD) values. FRAX calculators are available for 66 countries, representing well over 80% of the global population, and the tool is accessed by at least 228 countries/territories worldwide. Widely adopted within clinical guidelines for osteoporosis, FRAX is a key component in the initiation of targeted treatment to reduce the future burden of fractures.

Lead author, Professor Eugene McCloskey, Professor in Adult Bone Disease at the Department of Oncology and Metabolism, University of Sheffield, UK, stated: "As a global tool the FRAX website provides an excellent opportunity to explore the impact of the COVID-19 pandemic on osteoporosis, a major non-communicable disease (NCD) with a significant impact on older adults worldwide."

"The findings of this study reveal that, since the pandemic was officially declared by the WHO on March 11, there has been a dramatic drop in FRAX usage, averaging 58% but ranging up to 96%, with two-thirds of the 66 countries/territories evaluated showing reductions by at least 50%."

The analysis of FRAX usage showed:

 

  • Over February-April 2020, the FRAX website recorded 460,495 sessions from 184 countries, with 210,656 sessions in February alone.
  • In March and April, the number of sessions fell by 23.1% and 58.3% respectively, compared to February 2020, a pattern not observed over the same period in 2019.
  • In Europe, the majority of countries (24/31, 77.4%) reduced usage by at least 50% in April, with Poland, Slovakia, Czech Republic, Germany, Norway, Sweden and Finland showing smaller reductions (range -2.85% to -44.1%).
  • In Latin America, all eight countries studied showed reductions greater than 50%, with the smallest reduction seen in Brazil (-54.5%) and the greatest seen in Ecuador (-76.9%).
  • There were smaller reductions in Asia than elsewhere, partly related to earlier and less-marked nadirs in some countries (China, Taiwan, Hong Kong, South Korea and Vietnam).
  • There was no significant relationship between the reduction in FRAX usage and measures of disease burden such as COVID-attributed deaths per million of the population.

     

Metrics of FRAX usage captured by GoogleAnalytics (sessions rather than individual calculations) underestimate actual usage by about 30%, and additionally many FRAX assessments worldwide are conducted on bone densitometers, and were therefore not captured in the study.

As a result, it is estimated that approximately 175,000 patients were likely excluded from fracture risk assessment in April 2020, suggesting that over a 3-month period more than 0.5 million patients would be excluded from assessment, and a significant portion of those from necessary treatment.

Professor John Kanis, IOF Honorary President, Director of the Centre for Metabolic Bone Diseases at Sheffield and Professor at the Catholic University of Australia, stated: "The drastic reduction in FRAX usage underscores widespread concern that the COVID-19 pandemic is having a detrimental impact on the medium to long-term management and outcomes for many NCDs, with serious repercussions for individuals who are not able to access timely testing and treatment, including for osteoporosis."

"Availability and access to bone densitometry in many countries is low to begin with, and access to secondary care-based facilities such as Fracture Liaison Services has been further comprised or inhibited completely during the pandemic. We expect that FRAX, which can be undertaken remotely via telemedicine and has been shown to have a predictive value for fractures that is comparable to the use of bone density values alone, may be able to play a significant role in addressing this enormous backlog in assessments for osteoporosis."

###

References

1. McCloskey, E.V., Harvey, N.C., Johansson, H. et al. Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporos Int (2020). https://doi.org/10.1007/s00198-020-05542-6

2. FRAX Fracture Risk Assessment Tool https://www.sheffield.ac.uk/FRAX/

About FRAX

FRAX® is a simple calculation tool that integrates clinical information in a quantitative manner to predict a 10-year probability of major osteoporotic fracture for both women and men in different countries. The tool was developed at the Centre for Metabolic Bone Diseases, University of Sheffield, UK in collaboration with international researchers. It assists primary health-care providers to better target people in need of interventions to reduce fracture risk, thus improving the allocation of health-care resources towards patients most likely to benefit from treatment. The FRAX calculator, freely available for use online, is available for 66 countries and in 34 languages. It is the most widely used risk assessment tool, incorporated into national and regional guidelines worldwide. https://www.sheffield.ac.uk/FRAX/

About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 260 patient, medical and research societies, work together to make fracture prevention and healthy mobility a worldwide heath care priority. https://www.osteoporosis.foundation @iofbonehealth

About World Osteoporosis Day

World Osteoporosis Day (WOD) is held annually on October 20th. The campaign calls for global action to fight osteoporosis and related fractures. http://www.worldosteoporosisday.org

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
2.1387